Altimmune, Inc., a late clinical-stage biopharmaceutical company, has successfully secured $75.0 million in a recent funding round. This significant capital infusion is earmarked to support the ongoing development of its therapeutic pipeline, which focuses on improving the lives of people living with serious liver diseases. The investment underscores investor confidence in the company's strategic direction and its innovative approach to addressing critical health challenges.
Altimmune is dedicated to developing therapies aimed at improving the lives of individuals living with serious liver diseases. The company's lead program is a differentiated dual-action therapy. This therapy targets both glucagon and GLP-1 receptors in a balanced 1:1 ratio. It is currently in development for several significant conditions, including metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). These conditions represent areas of high unmet medical need, underscoring the potential impact of Altimmune's research.
This funding round represents a pivotal moment for Altimmune, providing substantial resources to accelerate its clinical development efforts and expand its research capabilities. The company plans to strategically deploy the newly raised capital to advance its ongoing clinical trials, further invest in critical research and development initiatives, and strengthen its operational infrastructure to support future growth. This investment reflects a clear endorsement of Altimmune's scientific approach and the potential of its lead therapeutic candidate to address significant unmet medical needs.
The successful completion of this funding round positions Altimmune to continue its mission of bringing innovative treatments to patients. The company remains focused on progressing its clinical programs through key development stages, with the ultimate goal of addressing serious liver diseases and delivering meaningful improvements in patient care.
